Cargando…

New Peptide Functionalized Nanostructured Lipid Carriers with CNS Drugs and Evaluation Anti-proliferative Activity

Nanoparticulate systems have been widely investigated as delivery vectors for efficient drug delivery in different diseases. Nanostructured lipid carriers (NLC) are composed of both solid and liquid lipids (glyceryl dibehenate and diethylene glycol monoethyl ether) and have demonstrated enhanced bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Sara, Marto, Joana, Gonçalves, Lídia M., Duarte, Diana, Soares, O. Salomé G. P., Vasques-Nóvoa, Francisco, Almeida, António J., Vale, Nuno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266917/
https://www.ncbi.nlm.nih.gov/pubmed/35806112
http://dx.doi.org/10.3390/ijms23137109
_version_ 1784743587800416256
author Silva, Sara
Marto, Joana
Gonçalves, Lídia M.
Duarte, Diana
Soares, O. Salomé G. P.
Vasques-Nóvoa, Francisco
Almeida, António J.
Vale, Nuno
author_facet Silva, Sara
Marto, Joana
Gonçalves, Lídia M.
Duarte, Diana
Soares, O. Salomé G. P.
Vasques-Nóvoa, Francisco
Almeida, António J.
Vale, Nuno
author_sort Silva, Sara
collection PubMed
description Nanoparticulate systems have been widely investigated as delivery vectors for efficient drug delivery in different diseases. Nanostructured lipid carriers (NLC) are composed of both solid and liquid lipids (glyceryl dibehenate and diethylene glycol monoethyl ether) and have demonstrated enhanced biological compatibility and increased drug loading capability. Furthermore, the use of peptides, in particular cell-penetrating peptides, to functionalize nanoparticles and enhance cell membrane permeation was explored in this paper. In this paper, we described the synthesis of a new conjugated of tranylcypromine with MAP. In addition, taking into consideration our previous results, this study developed different NLCs loaded with three central nervous system (CNS) drugs (tacrine (TAC), rasagiline (RAS), and tranylcypromine (TCP)) functionalized with model amphipathic peptide (MAP) and evaluated their activity against cancer cells. Particle size analysis demonstrated NLC presented less than 200 nm and a polydispersity index less than 0.3. Moreover, in vitro results showed that conjugation of MAP with drugs led to a higher decrease in cell viability of a neuroblastoma cell line and Caco-2 cell line, more than MAP alone. Furthermore, NLC encapsulation contributed to higher cellular delivery and enhanced toxic activity at lower concentrations when compared with free or co-administration drug-MAP conjugate.
format Online
Article
Text
id pubmed-9266917
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92669172022-07-09 New Peptide Functionalized Nanostructured Lipid Carriers with CNS Drugs and Evaluation Anti-proliferative Activity Silva, Sara Marto, Joana Gonçalves, Lídia M. Duarte, Diana Soares, O. Salomé G. P. Vasques-Nóvoa, Francisco Almeida, António J. Vale, Nuno Int J Mol Sci Article Nanoparticulate systems have been widely investigated as delivery vectors for efficient drug delivery in different diseases. Nanostructured lipid carriers (NLC) are composed of both solid and liquid lipids (glyceryl dibehenate and diethylene glycol monoethyl ether) and have demonstrated enhanced biological compatibility and increased drug loading capability. Furthermore, the use of peptides, in particular cell-penetrating peptides, to functionalize nanoparticles and enhance cell membrane permeation was explored in this paper. In this paper, we described the synthesis of a new conjugated of tranylcypromine with MAP. In addition, taking into consideration our previous results, this study developed different NLCs loaded with three central nervous system (CNS) drugs (tacrine (TAC), rasagiline (RAS), and tranylcypromine (TCP)) functionalized with model amphipathic peptide (MAP) and evaluated their activity against cancer cells. Particle size analysis demonstrated NLC presented less than 200 nm and a polydispersity index less than 0.3. Moreover, in vitro results showed that conjugation of MAP with drugs led to a higher decrease in cell viability of a neuroblastoma cell line and Caco-2 cell line, more than MAP alone. Furthermore, NLC encapsulation contributed to higher cellular delivery and enhanced toxic activity at lower concentrations when compared with free or co-administration drug-MAP conjugate. MDPI 2022-06-26 /pmc/articles/PMC9266917/ /pubmed/35806112 http://dx.doi.org/10.3390/ijms23137109 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Silva, Sara
Marto, Joana
Gonçalves, Lídia M.
Duarte, Diana
Soares, O. Salomé G. P.
Vasques-Nóvoa, Francisco
Almeida, António J.
Vale, Nuno
New Peptide Functionalized Nanostructured Lipid Carriers with CNS Drugs and Evaluation Anti-proliferative Activity
title New Peptide Functionalized Nanostructured Lipid Carriers with CNS Drugs and Evaluation Anti-proliferative Activity
title_full New Peptide Functionalized Nanostructured Lipid Carriers with CNS Drugs and Evaluation Anti-proliferative Activity
title_fullStr New Peptide Functionalized Nanostructured Lipid Carriers with CNS Drugs and Evaluation Anti-proliferative Activity
title_full_unstemmed New Peptide Functionalized Nanostructured Lipid Carriers with CNS Drugs and Evaluation Anti-proliferative Activity
title_short New Peptide Functionalized Nanostructured Lipid Carriers with CNS Drugs and Evaluation Anti-proliferative Activity
title_sort new peptide functionalized nanostructured lipid carriers with cns drugs and evaluation anti-proliferative activity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266917/
https://www.ncbi.nlm.nih.gov/pubmed/35806112
http://dx.doi.org/10.3390/ijms23137109
work_keys_str_mv AT silvasara newpeptidefunctionalizednanostructuredlipidcarrierswithcnsdrugsandevaluationantiproliferativeactivity
AT martojoana newpeptidefunctionalizednanostructuredlipidcarrierswithcnsdrugsandevaluationantiproliferativeactivity
AT goncalveslidiam newpeptidefunctionalizednanostructuredlipidcarrierswithcnsdrugsandevaluationantiproliferativeactivity
AT duartediana newpeptidefunctionalizednanostructuredlipidcarrierswithcnsdrugsandevaluationantiproliferativeactivity
AT soaresosalomegp newpeptidefunctionalizednanostructuredlipidcarrierswithcnsdrugsandevaluationantiproliferativeactivity
AT vasquesnovoafrancisco newpeptidefunctionalizednanostructuredlipidcarrierswithcnsdrugsandevaluationantiproliferativeactivity
AT almeidaantonioj newpeptidefunctionalizednanostructuredlipidcarrierswithcnsdrugsandevaluationantiproliferativeactivity
AT valenuno newpeptidefunctionalizednanostructuredlipidcarrierswithcnsdrugsandevaluationantiproliferativeactivity